Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aspen Aerogels (ASPN) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Aspen Aerogels (ASPN) over the last 13 years, with Q3 2025 value amounting to $150.7 million.

  • Aspen Aerogels' Cash & Equivalents rose 3279.47% to $150.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.7 million, marking a year-over-year increase of 3279.47%. This contributed to the annual value of $220.9 million for FY2024, which is 5808.56% up from last year.
  • Aspen Aerogels' Cash & Equivalents amounted to $150.7 million in Q3 2025, which was up 3279.47% from $167.6 million recorded in Q2 2025.
  • In the past 5 years, Aspen Aerogels' Cash & Equivalents ranged from a high of $281.3 million in Q4 2022 and a low of $17.2 million during Q1 2021
  • In the last 5 years, Aspen Aerogels' Cash & Equivalents had a median value of $134.3 million in 2023 and averaged $139.8 million.
  • In the last 5 years, Aspen Aerogels' Cash & Equivalents soared by 109170.68% in 2022 and then plummeted by 5109.35% in 2024.
  • Over the past 5 years, Aspen Aerogels' Cash & Equivalents (Quarter) stood at $76.6 million in 2021, then soared by 267.45% to $281.3 million in 2022, then plummeted by 50.34% to $139.7 million in 2023, then soared by 58.09% to $220.9 million in 2024, then crashed by 31.76% to $150.7 million in 2025.
  • Its Cash & Equivalents stands at $150.7 million for Q3 2025, versus $167.6 million for Q2 2025 and $192.0 million for Q1 2025.